Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis

Wojciech Łukowski

Open source

DOI
10.3389/fntpr.2026.1812441
Published
2026-07-07
Container
Frontiers in Natural Products
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fntpr.2026.1812441,
  title = {Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis},
  author = {Wojciech Łukowski},
  year = {2026},
  journal = {Frontiers in Natural Products},
  doi = {10.3389/fntpr.2026.1812441},
  url = {https://doi.org/10.3389/fntpr.2026.1812441}
}

RIS

TY  - JOUR
TI  - Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis
AU  - Wojciech Łukowski
PY  - 2026
JO  - Frontiers in Natural Products
DO  - 10.3389/fntpr.2026.1812441
UR  - https://doi.org/10.3389/fntpr.2026.1812441
ER  - 

APA

Łukowski, W. (2026). Δ9-tetrahydrocannabinol, a cannabis sativa–derived natural product, as a probe of endocannabinoid system plasticity in type 1 diabetes: a receptor-level, testable hypothesis. Frontiers in Natural Products. https://doi.org/10.3389/fntpr.2026.1812441

Source records